SeaStar Medical Holding Corp — fact timeline

SeaStar Medical Holding Corp shareholders approved Approve adjournment or postponement of Annual Meeting to permit further solicitation if necessary at the 2026-06-17 meeting.

“Proposal 4 . To approve a proposal to adjourn or postpone the Annual Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies if there are insufficient votes for, or otherwise in connection with, any of the proposals described above: Votes For Votes Against Abstentions Broker Non-Votes 2,035,262 123,747 21,905 —”

SeaStar Medical Holding Corp shareholders approved Ratify appointment of WithumSmith+Brown, PC as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-17 meeting.

“Proposal 3 . To ratify the appointment of WithumSmith+Brown, PC as our independent registered public accounting firm for the fiscal year ending December 31, 2026: Votes For Votes Against Abstentions Broker Non-Votes 2,151,096 22,746 7,072 —”

SeaStar Medical Holding Corp shareholders approved Approve amendment and restatement of 2022 Omnibus Incentive Plan to increase authorized shares from 207,046 to 896,546 at the 2026-06-17 meeting.

“Proposal 2 . To approve an amendment and restatement of the Company’s 2022 Omnibus Incentive Plan to increase the number of authorized shares of Common Stock from 207,046, as adjusted for a January 5, 2026, 1-for-10 reverse stock split, to 896,546: Votes For Votes Against Abstentions Broker Non-Votes 551,233 223,813 10,136 1,395,732”

SeaStar Medical Holding Corp shareholders approved Election of one Class I director to serve until the 2029 annual meeting of stockholders at the 2026-06-17 meeting.

“Proposal 1 . To elect one Class I director to serve until the 2029 annual meeting of stockholders, or until his successor shall have been duly elected and qualified: Nominee Votes For Votes Against Abstentions Broker Non-Votes John Neuman 757,141 23,212 4,829 1,395,732”

SeaStar Medical Holding Corp reported the three months ended March 31, 2026 results: revenue $0.5 million.

“from top-rated children’s hospitals, bringing the total customer base to 17 and building increased depth in customer orders. This led to first quarter 2026 net revenue of $0.5 million for QUELIMMUNE product sales, an increase of 69% versus the first quarter of 2025. ● Advanced enrollment in the NEUTRALIZE-AKI pivotal trial that is evaluating the Selective”

SeaStar Medical Holding Corp reported three months and year ended December 31, 2025 results: revenue approximately $2 million in net product revenue in 2026.

“On March 25, 2026, SeaStar Medical Holding Corp. (the "Company") issued a press release announcing its financial condition and results of operations for the three and twelve months ended December 31, 2025.”

SeaStar Medical Holding Corp issued common stock.

“On December 18, 2025, SeaStar Medical Holding Corporation (“the Company”) held a special meeting of the shareholders (the "Special Meeting") during which the stockholders approved a 1-for-10 reverse stock split of the Company's common stock (the "Reverse Split").”

SeaStar Medical Holding Corp received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“Company that, for the preceding 30 consecutive business days, the closing bid price for the Company’s common stock, par value $0.0001 per share (the “Common Stock”) was below the minimum $1.00 per share requirement for continued inclusion on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”). The notification received has no immediate effect on the Company’s Nasdaq listing. In accordance with Nasdaq rules, the Company has been provided an initial period of 180 calendar days, or until January 27, 2026 (the “Compliance Date”), to regain compliance”

SeaStar Medical Holding Corp received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“July 31, 2025, SeaStar Medical Holding Corporation (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that, for the preceding 30 consecutive business days, the closing bid price for the Company’s common stock, par value $0.0001 per share (the “Common Stock”) was below the minimum $1.00 per share requirement for continued inclusion on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”). The notification received has no immediate effect on”

SeaStar Medical Holding Corp received a nasdaq delisting notice notice regarding market value (rules 5550(b)(2)).

“December 24, 2024, the Company received written notification (the “Notification”) from Nasdaq stating that the Company had not regained compliance with the Rule. Pursuant to the Notification, the Securities are subject to delisting from Nasdaq on January 3, 2025, unless the Company requests a hearing before the Nasdaq Hearings Panel (the “Panel”) by December 31, 2024. The Company intends to appeal the delisting determination before the Panel and regain compliance with the Rule. Under Nasdaq rules, the delisting of the Securities will be stayed during the pendency of the appeal and during such”

Bernadette N. Vincent was elected as Director at SeaStar Medical Holding Corp.

“the Company issued a press release announcing the appointment of John Neuman and the two newly elected members to the Board, Ms. Jennifer A. Baird, and Ms. Bernadette N. Vincent.”

Jennifer A. Baird was elected as Director at SeaStar Medical Holding Corp.

“the Company issued a press release announcing the appointment of John Neuman and the two newly elected members to the Board, Ms. Jennifer A. Baird, and Ms. Bernadette N. Vincent.”

John Neuman was appointed as Class I Director at SeaStar Medical Holding Corp.

“the Board of Directors (the Board") of SeaStar Medical Holding Corporation (the "Company") appointed Mr. John Neuman as a Class I director, effective immediately”

Andres Lobo resigned as Director at SeaStar Medical Holding Corp.

“Mr. Andres Lobo informed the Board that he will resign as a director of the Company, effective as of June 5, 2024.”

SeaStar Medical Holding Corp reported financial results for the three months ended March 31, 2024.

“On May 14, 2024, SeaStar Medical Holding Corporation (the “Company”) issued a press release announcing its financial condition and results of operations for the fiscal quarter-ended March 31, 2024.”

SeaStar Medical Holding Corp: Amended and restated bylaws to reduce stockholder quorum threshold from majority to 33 1/3% and remove 'Acting in Concert' provisions (effective 2024-04-12).

“On April 12, 2024, the Board of Directors (the “Board”) of SeaStar Medical Holding Corporation (the “Company”) approved the amendment and restatement of the Company’s Amended and Restated Bylaws (the “Second Amended and Restated Bylaws”) to, among other things: • reduce the quorum threshold for meetings of stockholders from the holders of a majority of the common stock of the Company issued and outstanding and entitled to vote to the holders of at least 33 1/3% of the common stock of the Company issued and outstanding and entitled to vote; and • remove the “Acting in Concert” definition and provisions”

SeaStar Medical Holding Corp reported financial results for the 12 months ended December 31, 2023.

“SeaStar Medical Reports 2023 Financial Results and Provides a Business Update DENVER (April 17, 2024) – SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, reports financial results for the 12 months ended December 31, 2023 and provides a business update.”

SeaStar Medical Holding Corp reported that prior financial statements should not be relied upon.

“On March 21, 2024, after discussion with the Company’s management, the Audit Committee determined that a restatement of the Company’s audited financial statements for the fiscal year ended December 31, 2022 and unaudited interim financial statements for the fiscal quarters ended March 31, 2023, June 30, 2023 and September 30, 2023 would be appropriate”

SeaStar Medical Holding Corp terminated Common Stock Purchase Agreement with Tumim Stone Capital LLC valued at up to $100 million (effective 2024-02-15).

“On February 15, 2024, the Parties to the Purchase Agreement agreed by mutual consent and pursuant to its terms to terminate the Purchase Agreement, effective immediately.”

SeaStar Medical Holding Corp received a nasdaq hearing update notice regarding minimum bid price (rules 5550(a)(2)).

“February 6, 2024, the Company received notification from the Staff that the Company had regained compliance with the Market Value Rule. However, the Staff indicated the Company remains non-compliant with the Minimum Bid Price Rule and therefore, as previously disclosed, the Company should present its views with respect to this deficiency at its scheduled hearing in front of the Nasdaq Hearings Panel (the “Panel”) on March 12, 2024 (the “ Hearing ”). At the hearing, the Company will present its plan to regain compliance with the Minimum Bid Price Rule. Subject to the final written decision by t”

SeaStar Medical Holding Corp received a nasdaq compliance regained notice regarding market value (rules 5550(b)(2)).

“February 6, 2024, the Company received notification from the Staff that the Company had regained compliance with the Market Value Rule. However, the Staff indicated the Company remains non-compliant with the Minimum Bid Price Rule and therefore, as previously disclosed, the Company should present its views with respect to this deficiency at its scheduled hearing in front of the Nasdaq Hearings Panel (the “Panel”) on March 12, 2024 (the “ Hearing ”). At the hearing, the Company will present its plan to regain compliance with the Minimum Bid Price Rule. Subject to the final written decision by t”

SeaStar Medical Holding Corp entered into Securities Purchase Agreement with a single institutional investor valued at approximately $9.0 million (effective 2024-01-26).

“On January 26, 2024, SeaStar Medical Holdings Corporation (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with a single institutional investor (the “Purchaser”), pursuant to which the Company will issue to the Purchaser, (i) in a registered direct offering, 6,304,545 shares of the Company’s common stock (the “Shares”), par value $0.0001 per share (“Common Stock”), and pre-funded warrants to purchase 4,536,216 shares of Common Stock (the “Pre-Funded Warrants”) with an exercise price of $0.0001 per share, and (ii) in a concurrent private placement, series A warrants to purchase 10,840,761 shares of Common Stock (the “Series A Common Warrants”) and series B warrants to purchase 5,420,381 shares of Common Stock (the “Series B Common Warrants” and together with the Series A Common Warrants, the “Common Warrants”) each with an exercise price of $0.8302.”

Caryl Baron changed role as Vice President of Finance at SeaStar Medical Holding Corp.

“Also effective on January 10, 2024, Caryl Baron, who served as the Interim Chief Financial Officer of the Company since October 2022, will transition into the role of Vice President of Finance of the Company.”

David Green was appointed as Chief Financial Officer at SeaStar Medical Holding Corp.

“On January 10, 2024, the Board of Directors (the “Board”) of SeaStar Medical Holding Corporation (the “Company”) appointed David Green, age 61, as the Company’s Chief Financial Officer, effective as of January 10, 2024.”

SeaStar Medical Holding Corp received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(b)(1)).

“December 27, 2023. On December 27, 2023, the Company received notification from the Staff that the Company had not regained compliance with the Rule (the “Delisting Notice”). This is formal notification that the Nasdaq Hearings Panel (the “Panel”) will consider this matter in rendering a determination regarding the Company’s continued listing on The Nasdaq Capital Market, which is scheduled for Pursuant to Listing Rule 5810(d), the Company should present its views with respect to this additional deficiency at its Panel hearing to be held on March 12, 2024, as disclosed in Form 8-K Filed on Dec”

SeaStar Medical Holding Corp received a nasdaq delisting notice notice regarding market value (rules 5550(b)(2)).

“December 12, 2023, the Company received notification from the Staff that the Company had not regained compliance with the Market Value Rule (the “ Delisting Notice ”) or the alternative criteria. The Delisting Notice indicated that the Company’s common stock would be subject to delisting unless the Company timely requests a hearing before a Nasdaq Hearing Panel (the “ Panel ”). Accordingly, the Company intends to timely request a hearing before the Panel. The hearing request will stay any suspension or delisting action pending the hearing. Subject to the Company’s timely submission of a hearin”

SeaStar Medical Holding Corp engaged WithumSmith+Brown, PC as its auditor.

“On November 28, 2023, the Audit Committee appointed WithumSmith+Brown, PC (“Withum”) to serve as the principal accountant to audit the Company’s financial statements.”

Armanino LLP resigned as auditor of SeaStar Medical Holding Corp.

“2023, at which time Armanino’s resignation became effective. On November 28, 2023, the Audit Committee appointed WithumSmith+Brown, PC (“Withum”) to serve as the principal accountant to audit the Company’s financial”

SeaStar Medical Holding Corp reported financial results for three and nine months ended September 30, 2023.

“reports financial results for the three and nine months ended September 30, 2023”

SeaStar Medical Holding Corp: Increased authorized common stock from 100,000,000 shares to 500,000,000 shares (effective 2023-09-19).

“On September 19, 2023, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment to the Charter (the “Charter Amendment”) to effect the Authorized Shares Increase.”

SeaStar Medical Holding Corp shareholders approved Approve an amendment to the Company's 2022 Omnibus Equity Incentive Plan to increase the number of authorized shares under the Plan to 1,850,000 shares at the 2023-09-06 meeting.

“Proposal 4. To approve an amendment to the Company’s 2022 Omnibus Equity Incentive Plan to increase the number of authorized shares under the Plan to 1,850,000 shares. Votes For Votes Against Abstentions Broker Non-Votes 11,027,234 600,312 579 0”

SeaStar Medical Holding Corp shareholders approved Approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the potential issuance of shares of Common Stock issuable pursuant to the conversion or exchange of the Notes at the 2023-09-06 meeting.

“Proposal 3. To approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the potential issuance of shares of Common Stock issuable by the Company pursuant to the conversion or exchange of the Notes (as defined in the proxy statement). Votes For Votes Against Abstentions Broker Non-Votes 11,090,484 536,455 1,186 0”

SeaStar Medical Holding Corp shareholders approved Approve amendment to the Charter to increase the authorized number of shares of Common Stock from 100,000,000 to 500,000,000 at the 2023-09-06 meeting.

“Proposal 2. To approve an amendment to the Charter to increase the authorized number of shares of Common Stock from 100,000,000 shares to 500,000,000 shares. Votes For Votes Against Abstentions Broker Non-Votes 11,005,353 622,458 314 0”

SeaStar Medical Holding Corp shareholders approved Approve amendment to the Certificate of Incorporation to effect a reverse stock split of the Company's common stock at a ratio within a range of 1-for-10 to 1-for-100, without reducing authorized shares at the 2023-09-06 meeting.

“Proposal 1. To approve an amendment to the Third Amended and Restated Certificate of Incorporation of the Company (the “Charter”) to effect a reverse stock split of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) at a ratio to be determined by the Board of Directors within a range of 1-for-10 to 1-for-100, without reducing the authorized number of shares of the Common Stock, to be effected in the sole discretion of the Board of Directors at any time within one year of the date of the Special Meeting without further approval or authorization of stockholders. Votes For Votes Against Abstentions Broker Non-Votes 11,039,200 583,111 5,814 0”

SeaStar Medical Holding Corp amended convertible notes.

“the Company entered into a side letter with the Purchaser (the “Letter Agreement"), pursuant to which the Company agrees to adjust the conversion price of all Notes issued under the SPA”

SeaStar Medical Holding Corp incurred convertible notes of $543,478.26.

“On August 30, 2023, the Company closed the second tranche by issuing a Note with an initial conversion price equal to the lowest of (i) $0.20, (ii) the closing sale price of Common Stock on the trading day immediately preceding the date of conversion of the Note, and (iii) the average closing sale price of the Common Stock for the five (5) consecutive trading days immediately preceding the conversion date of the Note, in a principal amount of $543,478.26”

SeaStar Medical Holding Corp entered into Letter Agreement with an institutional investor (effective 2023-08-30).

“the Company entered into a side letter with the Purchaser (the “Letter Agreement”), pursuant to which the Company agrees to adjust the conversion price of all Notes issued under the SPA”

SeaStar Medical Holding Corp reported financial results for second quarter ended June 30, 2023.

“On August 14, 2023, SeaStar Medical Holding Corporation (the “Company”) issued a press release announcing its financial condition and results of operations for the fiscal quarter ended June 30, 2023.”

SeaStar Medical Holding Corp incurred senior notes of $543,478.26 with institutional investor.

“On August 7, 2023, the Company issued a Note, convertible into shares of Common Stock at an initial conversion price of $0.20, in a principal amount of $543,478.26”

SeaStar Medical Holding Corp entered into Letter Agreement with an institutional investor (effective 2023-08-07).

“In connection with the SPA Amendment and RRA Amendment, the Company and the Purchaser entered into that certain letter agreement (the “ Letter Agreement ”) providing for, among other things, (i) certain adjustment mechanisms for the Conversion Price (as defined in the Notes) of the existing Notes and additional Notes issued or to be issued under the Purchase Agreement, as amended, (ii) a 6-months waiver period of any cash payment obligations of the Company under each existing Note on each installment date and/or interest date, and (iii) the issuance of an additional Warrant to purchase an aggregate of 4,765,620 shares of Common Stock.”

SeaStar Medical Holding Corp amended First Amendment to Registration Rights Agreement with an institutional investor (effective 2023-08-07).

“Also on August 7, 2023, the Company and the Purchaser entered into that First Amendment to Registration Rights Agreement (the “ RRA Amendment ”), pursuant to which, commencing on the 91st calendar day after the effective date of the RRA Amendment, the Company shall use commercially reasonable efforts to file a resale registration statement within 15 calendar days after the Purchaser’s request therefor and to cause such registration statement to be declared effective by the SEC within certain time frames.”

SeaStar Medical Holding Corp amended First Amendment to Securities Purchase Agreement with an institutional investor (effective 2023-08-07).

“On August 7, 2023, the Company and the Purchaser entered into that First Amendment to Securities Purchase Agreement (the “ SPA Amendment ”), pursuant to which the provisions of the third closing in the Purchase Agreement are amended and, commencing after the Second Closing Date (as defined in the Purchase Agreement) and except for the Initial Funding (as defined below), the Purchaser shall have the discretion to purchase additional Securities in an aggregate principal amount, including the Initial Funding, of $2 million, provided that the Purchaser shall purchase additional Securities in an aggregate principal amount of $1 million in two tranches no later than September 5, 2023 (the “ Initial Funding ”).”

SeaStar Medical Holding Corp shareholders approved To ratify the appointment of Armanino LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023. at the 2023-06-28 meeting.

“Proposal 4. To ratify the appointment of Armanino LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023. Votes For Votes Against Abstentions Broker Non-Votes 10,771,442 16,575 7,692 —”

SeaStar Medical Holding Corp shareholders approved To approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the full issuance of shares of Common Stock issuable by the Company pursuant to the Company’s Equity Line of Credit (as defined in the proxy statement). at the 2023-06-28 meeting.

“Proposal 3. To approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the full issuance of shares of Common Stock issuable by the Company pursuant to the Company’s Equity Line of Credit (as defined in the proxy statement). Votes For Votes Against Abstentions Broker Non-Votes 9,883,905 27,629 7,160 877,015”

SeaStar Medical Holding Corp shareholders approved To approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the full issuance of shares of Common Stock issuable by the Company pursuant to the Convertible Notes (as defined in the proxy statement) and the Warrants (as defined in the proxy statement). at the 2023-06-28 meeting.

“Proposal 2. To approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the full issuance of shares of Common Stock issuable by the Company pursuant to the Convertible Notes (as defined in the proxy statement) and the Warrants (as defined in the proxy statement). Votes For Votes Against Abstentions Broker Non-Votes 9,883,905 27,629 7,160 877,015”

SeaStar Medical Holding Corp shareholders approved To elect two Class I Directors to serve until the 2026 annual meeting of stockholders, or until their successors shall have been duly elected and qualified. at the 2023-06-28 meeting.

“Proposal 1. To elect two Class I Directors to serve until the 2026 annual meeting of stockholders, or until their successors shall have been duly elected and qualified. Nominee Votes For Votes Against Abstentions Broker Non-Votes Andres Lobo 9,629,367 — 289,327 877,015 Rick Barnett 9,626,990 — 291,704 877,015”

SeaStar Medical Holding Corp received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“June 26, 2023, SeaStar Medical Holding Corporation (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that, for the preceding 30 consecutive business days, the closing bid price for the Company’s common stock, par value $0.0001 per share (the “Common Stock”) was below the minimum $1.00 per share requirement for continued inclusion on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”). The notification received has no immediate effect on”

SeaStar Medical Holding Corp received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).

“June 14, 2023, SeaStar Medical Holding Corporation (the “Company”) received a letter (the “Nasdaq Staff Deficiency Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty-five (35) consecutive business days, the Market Value of Listed Securities (“MVLS”) for the Company’s common stock, par value $0.0001 per share, had been below the $35 million minimum requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company has been provided an initial period of 180”

SeaStar Medical Holding Corp entered into Share Issuance and Settlement Agreement with Vellar Opportunity Fund SPV LLC – Series 4 (effective 2023-06-06).

“On June 6, 2023, SeaStar Medical Holding Corporation (the “Company”) and Vellar Opportunity Fund SPV LLC – Series 4 (“Vellar”) entered into the Share Issuance and Settlement Agreement (the “Agreement”), pursuant to which the Company agreed to issue and deliver to Vellar 1,000,000 shares of common stock, par value $0.0001 per share, of the Company (the “Settlement Shares”) in lieu of the obligation of the Company to pay certain maturity consideration to Vellar under the Prepaid Forward Purchase Agreement, dated as of October 17, 2022, between the Company and Vellar (the “FPA”), as a result of the occurrence of a VWAP Trigger Event (as defined under the FPA).”

SeaStar Medical Holding Corp reported the three months ended March 31, 2023 results: net income $5.3 million, EPS $0.40 per share.

“The net loss for the first quarter of 2023 was $5.3 million, or $0.40 per share, compared with a net loss of $1.0 million, or $0.14 per s”